BRYAN A MEHLHAFF
- Type
- Physician · Allopathic & Osteopathic Physicians / Urology
- Where
- SPRINGFIELD, OR
- NPI
- 1518978204
- Received
- $1,088,228 in 1,109 records, 2019 to 2025 ($1,045,572 general, $42,655 research)
- As principal investigator
- $9,384,518 of research payments to others in 912 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 131 | $123,331 |
| 2025 | Research payment | 2 | $31,257 |
| 2024 | General payment | 109 | $105,269 |
| 2024 | Ownership or investment interest | 4 | $0 |
| 2024 | Research payment | 3 | $5,080 |
| 2023 | General payment | 144 | $153,336 |
| 2023 | Ownership or investment interest | 2 | $0 |
| 2023 | Research payment | 3 | $990 |
| 2022 | General payment | 214 | $208,448 |
| 2022 | Ownership or investment interest | 2 | $0 |
| 2021 | General payment | 147 | $151,451 |
| 2021 | Ownership or investment interest | 2 | $0 |
| 2021 | Research payment | 1 | $5,328 |
| 2020 | General payment | 145 | $162,222 |
| 2020 | Ownership or investment interest | 2 | $0 |
| 2019 | General payment | 196 | $141,512 |
| 2019 | Ownership or investment interest | 2 | $0 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 275 | $647,048 |
| Consulting Fee | 73 | $190,678 |
| Travel and Lodging | 327 | $137,936 |
| Research payment | 9 | $42,655 |
| Honoraria | 44 | $39,905 |
| Food and Beverage | 362 | $29,902 |
| Education | 5 | $102 |
| Ownership or investment interest | 14 | $0 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-11-21 | SUN PHARMACEUTICAL INDUSTRIES INC. | $8,500 | Consulting Fee | Cash or cash equivalent | YONSA Drug, Oncology | 2025 | |
| 2025-11-21 | SUN PHARMACEUTICAL INDUSTRIES INC. | $392 | Travel and Lodging | In-kind items and services | YONSA Drug, Oncology | 2025 | |
| 2025-11-21 | SUN PHARMACEUTICAL INDUSTRIES INC. | $214 | Travel and Lodging | In-kind items and services | YONSA Drug, Oncology | 2025 | |
| 2025-11-21 | SUN PHARMACEUTICAL INDUSTRIES INC. | $207 | Travel and Lodging | Cash or cash equivalent | YONSA Drug, Oncology | 2025 | |
| 2025-11-20 | SUN PHARMACEUTICAL INDUSTRIES INC. | $551 | Travel and Lodging | In-kind items and services | YONSA Drug, Oncology | 2025 | |
| 2025-11-20 | SUN PHARMACEUTICAL INDUSTRIES INC. | $239 | Travel and Lodging | In-kind items and services | YONSA Drug, Oncology | 2025 | |
| 2025-11-19 | Janssen Pharmaceuticals, Inc | $1,175 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-18 | Procept Biorobotics Corporation | $81 | Food and Beverage | In-kind items and services | AQUABEAM ROBOTIC SYSTEM Device, Urology | 2025 | |
| 2025-11-13 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-07 | Janssen Biotech, Inc. | $26 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2025 | |
| 2025-11-06 | Janssen Pharmaceuticals, Inc | $146 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-22 | Bayer Healthcare Pharmaceuticals Inc. | $4,704 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Nubeqa Drug, Oncology | 2025 | |
| 2025-10-22 | Novartis Pharmaceuticals Corporation | $675 | Consulting Fee | Cash or cash equivalent | PLUVICTO Drug, Oncology | 2025 | |
| 2025-10-22 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-10-22 | Novartis Pharmaceuticals Corporation | $0 | Food and Beverage | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-10-21 | Janssen Scientific Affairs, LLC | $132 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2025 | |
| 2025-10-20 | Ferring Pharmaceuticals Inc. | $1,518 | Consulting Fee | Cash or cash equivalent | ADSTILADRIN Biological, ONCOLOGY | 2025 | |
| 2025-10-16 | Ferring Pharmaceuticals Inc. | $166 | Food and Beverage | In-kind items and services | ADSTILADRIN Biological, ONCOLOGY | 2025 | |
| 2025-10-16 | Janssen Biotech, Inc. | $72 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2025 | |
| 2025-10-05 | SUN PHARMACEUTICAL INDUSTRIES INC. | $6,798 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | YONSA Drug, Oncology | 2025 | |
| 2025-10-01 | Dendreon Pharmaceuticals LLC | $4,550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2025 | |
| 2025-10-01 | Dendreon Pharmaceuticals LLC | $489 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2025 | |
| 2025-10-01 | Dendreon Pharmaceuticals LLC | $276 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2025 | |
| 2025-10-01 | Dendreon Pharmaceuticals LLC | $190 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2025 | |
| 2025-10-01 | Dendreon Pharmaceuticals LLC | $144 | Food and Beverage | In-kind items and services | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2025 | |
| 2025-09-19 | Telix Pharmaceuticals | $205 | Food and Beverage | In-kind items and services | ILLUCCIX Drug, PROSTATE CANCER DIAGNOSIS | 2025 | |
| 2025-09-18 | AstraZeneca UK Limited | $2,240 | Consulting Fee | Cash or cash equivalent | Truqap Drug, Oncology | 2025 | |
| 2025-09-04 | Bayer Healthcare Pharmaceuticals Inc. | $21 | Food and Beverage | In-kind items and services | Nubeqa Drug, Oncology | 2025 | |
| 2025-08-15 | Bayer Healthcare Pharmaceuticals Inc. | $431 | Travel and Lodging | In-kind items and services | Nubeqa Drug, Oncology | 2025 | |
| 2025-08-15 | Janssen Biotech, Inc. | $277 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-08-06 | Valencia Technologies Corporation | $27 | Food and Beverage | Cash or cash equivalent | eCoin Device Kit Device, Treat Urgency Urinary Incontinence | 2025 | |
| 2025-07-17 | Novartis Pharmaceuticals Corporation | $2,700 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-17 | Novartis Pharmaceuticals Corporation | $2,700 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-12 | Novartis Pharmaceuticals Corporation | $8,750 | Consulting Fee | Cash or cash equivalent | PLUVICTO Drug, Oncology | 2025 | |
| 2025-07-12 | Novartis Pharmaceuticals Corporation | $486 | Travel and Lodging | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-07-12 | Novartis Pharmaceuticals Corporation | $92 | Food and Beverage | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-07-12 | Novartis Pharmaceuticals Corporation | $83 | Food and Beverage | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-07-12 | Novartis Pharmaceuticals Corporation | $74 | Travel and Lodging | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-07-11 | Novartis Pharmaceuticals Corporation | $1,807 | Travel and Lodging | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-07-11 | Novartis Pharmaceuticals Corporation | $241 | Travel and Lodging | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-07-11 | Novartis Pharmaceuticals Corporation | $219 | Travel and Lodging | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-07-11 | Novartis Pharmaceuticals Corporation | $188 | Travel and Lodging | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-07-11 | Novartis Pharmaceuticals Corporation | $185 | Travel and Lodging | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-07-11 | Janssen Biotech, Inc. | $9 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2025 | |
| 2025-06-27 | Bayer Healthcare Pharmaceuticals Inc. | $1,176 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Nubeqa Drug, Oncology | 2025 | |
| 2025-06-19 | Janssen Biotech, Inc. | $4,162 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-06-16 | Janssen Biotech, Inc. | $791 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-06-13 | Janssen Biotech, Inc. | $140 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2025 | |
| 2025-06-13 | Janssen Biotech, Inc. | $28 | Travel and Lodging | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-06-13 | Janssen Biotech, Inc. | $12 | Travel and Lodging | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-06-11 | Janssen Biotech, Inc. | $147 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-06-05 | Dendreon Pharmaceuticals LLC | $29,902 | Research payment | Cash or cash equivalent | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | PROVONE STUDY | 2025 |
| 2025-06-05 | Dendreon Pharmaceuticals LLC | $1,355 | Research payment | Cash or cash equivalent | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | PROVONE STUDY | 2025 |
| 2025-06-05 | Janssen Biotech, Inc. | $14 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2025 | |
| 2025-06-03 | Bayer Healthcare Pharmaceuticals Inc. | $9,024 | Consulting Fee | Cash or cash equivalent | Nubeqa Drug, Oncology | 2025 | |
| 2025-06-03 | Bayer Healthcare Pharmaceuticals Inc. | $472 | Travel and Lodging | In-kind items and services | Nubeqa Drug, Oncology | 2025 | |
| 2025-06-03 | Bayer Healthcare Pharmaceuticals Inc. | $65 | Travel and Lodging | In-kind items and services | Nubeqa Drug, Oncology | 2025 | |
| 2025-06-03 | Bayer Healthcare Pharmaceuticals Inc. | $56 | Travel and Lodging | In-kind items and services | Nubeqa Drug, Oncology | 2025 | |
| 2025-06-02 | Bayer Healthcare Pharmaceuticals Inc. | $393 | Travel and Lodging | In-kind items and services | Nubeqa Drug, Oncology | 2025 | |
| 2025-06-02 | Bayer Healthcare Pharmaceuticals Inc. | $197 | Travel and Lodging | In-kind items and services | Nubeqa Drug, Oncology | 2025 | |
| 2025-06-02 | Bayer Healthcare Pharmaceuticals Inc. | $135 | Food and Beverage | In-kind items and services | Nubeqa Drug, Oncology | 2025 | |
| 2025-05-29 | Janssen Biotech, Inc. | $693 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-05-23 | Janssen Biotech, Inc. | $1,110 | Consulting Fee | Cash or cash equivalent | ERLEADA Drug, Oncology | 2025 | |
| 2025-05-23 | Janssen Biotech, Inc. | $416 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-05-13 | Janssen Biotech, Inc. | $28 | Travel and Lodging | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-05-13 | Janssen Biotech, Inc. | $15 | Travel and Lodging | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-05-09 | Janssen Biotech, Inc. | $285 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-05-08 | Janssen Biotech, Inc. | $4,162 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-05-06 | Janssen Biotech, Inc. | $122 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-05-02 | Dendreon Pharmaceuticals LLC | $156 | Food and Beverage | In-kind items and services | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2025 | |
| 2025-05-01 | Janssen Biotech, Inc. | $40 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2025 | |
| 2025-04-29 | Dendreon Pharmaceuticals LLC | $4,550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2025 | |
| 2025-04-29 | Dendreon Pharmaceuticals LLC | $403 | Travel and Lodging | Cash or cash equivalent | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2025 | |
| 2025-04-29 | Dendreon Pharmaceuticals LLC | $173 | Travel and Lodging | Cash or cash equivalent | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2025 | |
| 2025-04-29 | Dendreon Pharmaceuticals LLC | $150 | Food and Beverage | In-kind items and services | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2025 | |
| 2025-04-29 | Dendreon Pharmaceuticals LLC | $56 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2025 | |
| 2025-04-28 | Janssen Biotech, Inc. | $266 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-04-27 | Janssen Global Services, LLC | $923 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-04-27 | Janssen Global Services, LLC | $448 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-04-27 | Janssen Global Services, LLC | $49 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-04-27 | Janssen Global Services, LLC | $40 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-04-27 | Janssen Global Services, LLC | $13 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-04-26 | Janssen Global Services, LLC | $1,150 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-04-26 | Janssen Global Services, LLC | $116 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-04-26 | Janssen Global Services, LLC | $51 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-04-26 | Janssen Global Services, LLC | $16 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-04-26 | Janssen Global Services, LLC | $10 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-04-18 | Dendreon Pharmaceuticals LLC | $30 | Food and Beverage | In-kind items and services | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2025 | |
| 2025-04-16 | Janssen Biotech, Inc. | $5 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-04-10 | Janssen Biotech, Inc. | $62 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-22 | Novartis Pharmaceuticals Corporation | $120 | Food and Beverage | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-03-20 | TOLMAR, INC. | $120 | Food and Beverage | In-kind items and services | ELIGARD Drug, Prostate Cancer | 2025 | |
| 2025-03-20 | pharmaand GmbH | $120 | Food and Beverage | In-kind items and services | Rubraca Drug, PARP inhibitor | 2025 | |
| 2025-03-16 | Sumitomo Pharma America, Inc. | $25 | Food and Beverage | In-kind items and services | ORGOVYX Drug, PROSTATE CANCER | 2025 | |
| 2025-03-13 | Janssen Biotech, Inc. | $123 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2025 | |
| 2025-03-10 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-03-08 | Bayer Healthcare Pharmaceuticals Inc. | $1,176 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Nubeqa Drug, Oncology | 2025 | |
| 2025-03-06 | SUN PHARMACEUTICAL INDUSTRIES INC. | $7,500 | Consulting Fee | Cash or cash equivalent | YONSA Drug, Oncology | 2025 | |
| 2025-03-06 | Janssen Biotech, Inc. | $336 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-03-06 | SUN PHARMACEUTICAL INDUSTRIES INC. | $161 | Travel and Lodging | Cash or cash equivalent | YONSA Drug, Oncology | 2025 | |
| 2025-03-01 | Dendreon Pharmaceuticals LLC | $6,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2025 | |
| 2025-03-01 | Dendreon Pharmaceuticals LLC | $516 | Travel and Lodging | Cash or cash equivalent | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2025 | |
| 2025-03-01 | Dendreon Pharmaceuticals LLC | $436 | Travel and Lodging | Cash or cash equivalent | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2025 | |
| 2025-03-01 | Dendreon Pharmaceuticals LLC | $345 | Travel and Lodging | Cash or cash equivalent | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2025 | |
| 2025-03-01 | Dendreon Pharmaceuticals LLC | $64 | Food and Beverage | In-kind items and services | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2025 | |
| 2025-02-26 | PFIZER INC. | $423 | Travel and Lodging | In-kind items and services | XTANDI Drug, ONCOLOGY | 2025 | |
| 2025-02-25 | Janssen Biotech, Inc. | $555 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-02-22 | SUN PHARMACEUTICAL INDUSTRIES INC. | $246 | Travel and Lodging | In-kind items and services | YONSA Drug, Oncology | 2025 | |
| 2025-02-22 | SUN PHARMACEUTICAL INDUSTRIES INC. | $200 | Travel and Lodging | In-kind items and services | YONSA Drug, Oncology | 2025 | |
| 2025-02-22 | SUN PHARMACEUTICAL INDUSTRIES INC. | $58 | Food and Beverage | In-kind items and services | YONSA Drug, Oncology | 2025 | |
| 2025-02-22 | SUN PHARMACEUTICAL INDUSTRIES INC. | $43 | Food and Beverage | In-kind items and services | YONSA Drug, Oncology | 2025 | |
| 2025-02-22 | SUN PHARMACEUTICAL INDUSTRIES INC. | $34 | Food and Beverage | In-kind items and services | YONSA Drug, Oncology | 2025 | |
| 2025-02-19 | Janssen Scientific Affairs, LLC | $57 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2025 | |
| 2025-02-17 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,097 | Travel and Lodging | In-kind items and services | YONSA Drug, Oncology | 2025 | |
| 2025-02-17 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-02-11 | PFIZER INC. | $720 | Travel and Lodging | In-kind items and services | XTANDI Drug, ONCOLOGY | 2025 | |
| 2025-02-11 | PFIZER INC. | $159 | Travel and Lodging | In-kind items and services | XTANDI Drug, ONCOLOGY | 2025 | |
| 2025-02-11 | PFIZER INC. | $90 | Travel and Lodging | In-kind items and services | XTANDI Drug, ONCOLOGY | 2025 | |
| 2025-02-11 | PFIZER INC. | $65 | Food and Beverage | In-kind items and services | XTANDI Drug, ONCOLOGY | 2025 | |
| 2025-02-08 | PFIZER INC. | $230 | Travel and Lodging | In-kind items and services | XTANDI Drug, ONCOLOGY | 2025 | |
| 2025-02-08 | PFIZER INC. | $211 | Travel and Lodging | In-kind items and services | XTANDI Drug, ONCOLOGY | 2025 | |
| 2025-02-07 | PFIZER INC. | $5,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | 2025 | |
| 2025-02-05 | PFIZER INC. | $114 | Food and Beverage | In-kind items and services | XTANDI Drug, ONCOLOGY | 2025 | |
| 2025-01-30 | PFIZER INC. | $780 | Travel and Lodging | In-kind items and services | XTANDI Drug, ONCOLOGY | 2025 | |
| 2025-01-30 | Procept Biorobotics Corporation | $112 | Food and Beverage | In-kind items and services | AQUABEAM ROBOTIC SYSTEM Device, Urology | 2025 | |
| 2025-01-29 | Bayer Healthcare Pharmaceuticals Inc. | $489 | Consulting Fee | Cash or cash equivalent | Nubeqa Drug, Oncology | 2025 | |
| 2025-01-10 | Bayer Healthcare Pharmaceuticals Inc. | $8,802 | Consulting Fee | Cash or cash equivalent | Nubeqa Drug, Oncology | 2025 | |
| 2025-01-10 | Bayer Healthcare Pharmaceuticals Inc. | $420 | Travel and Lodging | In-kind items and services | Nubeqa Drug, Oncology | 2025 | |
| 2025-01-10 | Bayer Healthcare Pharmaceuticals Inc. | $309 | Travel and Lodging | In-kind items and services | Nubeqa Drug, Oncology | 2025 | |
| 2025-01-10 | Bayer Healthcare Pharmaceuticals Inc. | $197 | Travel and Lodging | In-kind items and services | Nubeqa Drug, Oncology | 2025 | |
| 2025-01-09 | Bayer Healthcare Pharmaceuticals Inc. | $276 | Travel and Lodging | In-kind items and services | Nubeqa Drug, Oncology | 2025 | |
| 2025-01-09 | Bayer Healthcare Pharmaceuticals Inc. | $212 | Travel and Lodging | In-kind items and services | Nubeqa Drug, Oncology | 2025 | |
| 2025-01-06 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2024-12-12 | Astellas Pharma US Inc | $6,020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Xtandi Drug, Oncology | 2024 | |
| 2024-12-12 | Astellas Pharma US Inc | $673 | Travel and Lodging | Cash or cash equivalent | Xtandi Drug, Oncology | 2024 | |
| 2024-12-12 | Astellas Pharma US Inc | $565 | Travel and Lodging | Cash or cash equivalent | Xtandi Drug, Oncology | 2024 | |
| 2024-12-12 | Astellas Pharma US Inc | $5 | Food and Beverage | In-kind items and services | Xtandi Drug, Oncology | 2024 | |
| 2024-12-09 | Janssen Biotech, Inc. | $1,350 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ERLEADA Drug, Oncology | 2024 | |
| 2024-12-09 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-12-04 | Janssen Biotech, Inc. | $47 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2024 | |
| 2024-11-26 | PFIZER INC. | $3,200 | Research payment | In-kind items and services | XTANDI Drug, ONCOLOGY | XTANDI CLINICAL PUBLICATION PROGRAM | 2024 |
| 2024-11-22 | Ferring Pharmaceuticals Inc. | $55 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-11-22 | Dendreon Pharmaceuticals LLC | $37 | Food and Beverage | In-kind items and services | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2024 | |
| 2024-11-21 | Dendreon Pharmaceuticals LLC | $136 | Food and Beverage | In-kind items and services | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2024 | |
| 2024-11-19 | Janssen Biotech, Inc. | $28 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2024 | |
| 2024-11-15 | Janssen Biotech, Inc. | $42 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2024 | |
| 2024-11-14 | Astellas Pharma US Inc | $164 | Food and Beverage | In-kind items and services | Xtandi Drug, Oncology | 2024 | |
| 2024-11-12 | AstraZeneca Pharmaceuticals LP | $1,920 | Consulting Fee | Cash or cash equivalent | IMFINZI Biological, Oncology | 2024 | |
| 2024-11-07 | Sumitomo Pharma America, Inc. | $83 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | 2024 | |
| 2024-11-07 | Sumitomo Pharma America, Inc. | $18 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | 2024 | |
| 2024-10-31 | Janssen Biotech, Inc. | $675 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ERLEADA Drug, Oncology | 2024 | |
| 2024-10-29 | Janssen Biotech, Inc. | $114 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2024 | |
| 2024-10-28 | Dendreon Pharmaceuticals LLC | $142 | Food and Beverage | In-kind items and services | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2024 | |
| 2024-10-28 | Dendreon Pharmaceuticals LLC | $115 | Food and Beverage | In-kind items and services | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2024 | |
| 2024-10-28 | Dendreon Pharmaceuticals LLC | $27 | Food and Beverage | In-kind items and services | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2024 | |
| 2024-10-24 | Janssen Biotech, Inc. | $2,180 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-10-24 | UROGEN PHARMA, INC. | $2,040 | Honoraria | Cash or cash equivalent | 2024 | ||
| 2024-10-24 | Janssen Biotech, Inc. | $140 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2024 | |
| 2024-10-24 | Janssen Biotech, Inc. | $79 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-24 | Janssen Biotech, Inc. | $48 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-24 | UROGEN PHARMA, INC. | $33 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-24 | Janssen Biotech, Inc. | $32 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2024 | |
| 2024-10-23 | Ferring Pharmaceuticals Inc. | $20 | Food and Beverage | In-kind items and services | ADSTILADRIN Biological, ONCOLOGY | 2024 | |
| 2024-10-21 | Sumitomo Pharma America, Inc. | $6,715 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | 2024 | |
| 2024-10-17 | Dendreon Pharmaceuticals LLC | $2,362 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2024 | |
| 2024-10-17 | Sumitomo Pharma America, Inc. | $277 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | ORGOVYX Drug, HORMONE THERAPY | 2024 | |
| 2024-10-17 | Dendreon Pharmaceuticals LLC | $37 | Food and Beverage | In-kind items and services | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2024 | |
| 2024-10-16 | Sumitomo Pharma America, Inc. | $124 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | ORGOVYX Drug, HORMONE THERAPY | 2024 | |
| 2024-10-14 | Janssen Biotech, Inc. | $1,350 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ERLEADA Drug, Oncology | 2024 | |
| 2024-10-09 | Janssen Biotech, Inc. | $118 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2024 | |
| 2024-09-21 | Janssen Biotech, Inc. | $87 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2024 | |
| 2024-09-20 | Bayer Healthcare Pharmaceuticals Inc. | $139 | Food and Beverage | In-kind items and services | Nubeqa Drug, Oncology | 2024 | |
| 2024-09-14 | Janssen Biotech, Inc. | $30 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2024 | |
| 2024-09-03 | Sumitomo Pharma America, Inc. | $621 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | ORGOVYX Drug, HORMONE THERAPY | 2024 | |
| 2024-08-13 | Janssen Biotech, Inc. | $16 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2024 | |
| 2024-08-08 | Sumitomo Pharma America, Inc. | $2,820 | Consulting Fee | Cash or cash equivalent | GEMTESA Drug, UROLOGY | 2024 | |
| 2024-08-06 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | PLUVICTO Drug, Oncology | 2024 | |
| 2024-07-12 | Sumitomo Pharma America, Inc. | $6,715 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | 2024 | |
| 2024-07-03 | Bayer Healthcare Pharmaceuticals Inc. | $4,998 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Nubeqa Drug, Oncology | 2024 | |
| 2024-06-28 | Sumitomo Pharma America, Inc. | $107 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | 2024 | |
| 2024-06-19 | Sumitomo Pharma America, Inc. | $125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | ORGOVYX Drug, HORMONE THERAPY | 2024 | |
| 2024-06-07 | Sumitomo Pharma America, Inc. | $125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | GEMTESA Drug, UROLOGY | 2024 | |
| 2024-06-07 | Sumitomo Pharma America, Inc. | $35 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | GEMTESA Drug, UROLOGY | 2024 | |
| 2024-05-31 | PFIZER INC. | $20 | Food and Beverage | In-kind items and services | XTANDI Drug, ONCOLOGY | 2024 | |
| 2024-05-30 | Sumitomo Pharma America, Inc. | $1,311 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | ORGOVYX Drug, HORMONE THERAPY | 2024 | |
| 2024-05-22 | Ferring Pharmaceuticals Inc. | $2,450 | Consulting Fee | Cash or cash equivalent | ADSTILADRIN Biological, ONCOLOGY | 2024 | |
| 2024-05-16 | Ferring Pharmaceuticals Inc. | $105 | Food and Beverage | In-kind items and services | ADSTILADRIN Biological, ONCOLOGY | 2024 | |
| 2024-05-15 | Bayer Healthcare Pharmaceuticals Inc. | $664 | Travel and Lodging | In-kind items and services | Nubeqa Drug, Oncology | 2024 | |
| 2024-05-09 | IMMUNITYBIO, INC. | $20 | Food and Beverage | In-kind items and services | ANKTIVA Drug, Immunotherapy | 2024 | |
| 2024-05-06 | Sumitomo Pharma America, Inc. | $28 | Food and Beverage | In-kind items and services | ORGOVYX Drug, HORMONE THERAPY | 2024 | |
| 2024-05-03 | Janssen Biotech, Inc. | $675 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ERLEADA Drug, Oncology | 2024 | |
| 2024-04-30 | Janssen Biotech, Inc. | $1,012 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ERLEADA Drug, Oncology | 2024 | |
| 2024-04-30 | AstraZeneca Pharmaceuticals LP | $450 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2024 | |
| 2024-04-05 | Janssen Biotech, Inc. | $136 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2024 | |
| 2024-04-04 | PFIZER INC. | $70 | Travel and Lodging | In-kind items and services | TALZENNA Drug, ONCOLOGY | 2024 | |
| 2024-03-26 | UROGEN PHARMA, INC. | $1,020 | Honoraria | Cash or cash equivalent | JELMYTO Drug, UROTHELIAL CANCER | 2024 | |
| 2024-03-26 | Sumitomo Pharma America, Inc. | $377 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | 2024 | |
| 2024-03-26 | Sumitomo Pharma America, Inc. | $99 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | 2024 | |
| 2024-03-26 | Sumitomo Pharma America, Inc. | $54 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | 2024 | |
| 2024-03-26 | Sumitomo Pharma America, Inc. | $44 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | 2024 |
The latest 200 records of 1,109.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-31 | Merck Sharp & Dohme LLC | OREGON UROLOGY INSTITUTE | $37,491 | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2025 |
| 2025-12-19 | Janssen Research & Development, LLC | OREGON UROLOGY INSTITUTE | $3,556 | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Lo | 2025 |
| 2025-12-18 | Janssen Research & Development, LLC | OREGON UROLOGY INSTITUTE | $1,042 | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Lo | 2025 |
| 2025-12-15 | Janssen Research & Development, LLC | OREGON UROLOGY INSTITUTE | $2,186 | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to | 2025 |
| 2025-12-01 | PFIZER INC. | OREGON UROLOGY INSTITUTE | $46,207 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-11-28 | PFIZER INC. | OREGON UROLOGY INSTITUTE | $46,207 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-11-27 | Janssen Research & Development, LLC | OREGON UROLOGY INSTITUTE | $17,752 | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to | 2025 |
| 2025-11-15 | Novartis Pharmaceuticals Corporation | OREGON UROLOGY INSTITUTE | $17,228 | A Phase II, Open-label, Multi-Center, Randomized Study Comparing the Combination of Lutetium (177Lu) Vipivotide Tetraxet | 2025 |
| 2025-11-14 | Dendreon Pharmaceuticals LLC | OREGON UROLOGY INSTITUE PC | $26,476 | PROVONE STUDY | 2025 |
| 2025-11-13 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $6,882 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-11-13 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $300 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-11-12 | Bayer Healthcare Pharmaceuticals Inc. | Unio Specialty Care Cancer Center Of Excellence San Diego | $452 | BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients | 2025 |
| 2025-11-06 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $1,015 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-11-06 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $1,261 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-11-06 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $1,092 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-10-30 | Janssen Research & Development, LLC | OREGON UROLOGY INSTITUTE | $1,195 | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to | 2025 |
| 2025-10-27 | Novartis Pharmaceuticals Corporation | OREGON UROLOGY INSTITUTE | $354,066 | An International Prospective Open-label, Multi-center, Randomized, non-comparative Phase II Study of Lutetium [177Lu] vi | 2025 |
| 2025-10-27 | Novartis Pharmaceuticals Corporation | OREGON UROLOGY INSTITUTE | $81,929 | An International Prospective Open-label, Multi-center, Randomized Phase III Study comparing [177Lu] Lu-PSMA-617 versus O | 2025 |
| 2025-10-23 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $6,882 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-10-23 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $600 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-10-02 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $1,092 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-10-02 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $1,092 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-09-29 | Janssen Research & Development, LLC | OREGON UROLOGY INSTITUTE | $4,802 | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to | 2025 |
| 2025-09-10 | PFIZER INC. | OREGON UROLOGY INSTITUTE | $46,207 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-09-09 | PFIZER INC. | OREGON UROLOGY INSTITUTE | $46,207 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-09-04 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $1,092 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-09-04 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $1,092 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-08-28 | Janssen Research & Development, LLC | OREGON UROLOGY INSTITUTE | $872 | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to | 2025 |
| 2025-08-18 | Janssen Research & Development, LLC | OREGON UROLOGY INSTITUTE | $1,042 | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Lo | 2025 |
| 2025-08-11 | Janssen Research & Development, LLC | OREGON UROLOGY INSTITUTE | $3,556 | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Lo | 2025 |
| 2025-08-08 | Dendreon Pharmaceuticals LLC | OREGON UROLOGY INSTITUE PC | $36,369 | PROVONE STUDY | 2025 |
| 2025-08-08 | Dendreon Pharmaceuticals LLC | OREGON UROLOGY INSTITUE PC | $42,473 | PROVONE STUDY | 2025 |
| 2025-07-28 | Janssen Research & Development, LLC | OREGON UROLOGY INSTITUTE | $872 | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to | 2025 |
| 2025-07-24 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $293 | PROSPER A MULTINATIONAL PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PA | 2025 |
| 2025-07-24 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $293 | PROSPER A MULTINATIONAL PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PA | 2025 |
| 2025-07-03 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $5,391 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-07-03 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $150 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-07-03 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $273 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-07-03 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $273 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-07-03 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $1,092 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-07-03 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $1,092 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-06-27 | Janssen Research & Development, LLC | OREGON UROLOGY INSTITUTE | $3,930 | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to | 2025 |
| 2025-06-25 | Merck Sharp & Dohme LLC | OREGON UROLOGY INSTITUTE | $1,011 | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2025 |
| 2025-06-13 | Janssen Research & Development, LLC | OREGON UROLOGY INSTITUTE | $9,739 | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to | 2025 |
| 2025-06-12 | PFIZER INC. | OREGON UROLOGY INSTITUTE | $46,206 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-06-11 | PFIZER INC. | OREGON UROLOGY INSTITUTE | $46,207 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-06-11 | PFIZER INC. | OREGON UROLOGY INSTITUTE | $46,206 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-06-10 | Bayer Healthcare Pharmaceuticals Inc. | Unio Specialty Care Cancer Center Of Excellence San Diego | $1,984 | BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients | 2025 |
| 2025-06-05 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $273 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-06-05 | Dendreon Pharmaceuticals LLC | OREGON UROLOGY INSTITUE PC | $1,355 | ProvONE | 2025 |
| 2025-06-05 | Dendreon Pharmaceuticals LLC | OREGON UROLOGY INSTITUE PC | $29,902 | ProvONE | 2025 |
| 2025-06-05 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $273 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-06-05 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $273 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-06-05 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $273 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-06-05 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $273 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-06-05 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $273 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-05-29 | Janssen Research & Development, LLC | OREGON UROLOGY INSTITUTE | $1,042 | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Lo | 2025 |
| 2025-05-08 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $273 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-05-08 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $273 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-05-08 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $596 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-05-08 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $1,092 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-05-08 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $1,092 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-05-08 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $273 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-05-08 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $273 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-05-08 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $273 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-05-08 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $1,092 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-05-01 | Janssen Research & Development, LLC | OREGON UROLOGY INSTITUTE | $872 | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to | 2025 |
| 2025-04-17 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $9,123 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-04-11 | Janssen Research & Development, LLC | OREGON UROLOGY INSTITUTE | $29,217 | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to | 2025 |
| 2025-04-03 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $1,092 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-03-31 | Janssen Research & Development, LLC | OREGON UROLOGY INSTITUTE | $4,372 | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to | 2025 |
| 2025-03-24 | PFIZER INC. | OREGON UROLOGY INSTITUTE | $46,206 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-03-23 | PFIZER INC. | OREGON UROLOGY INSTITUTE | $46,206 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-03-23 | PFIZER INC. | OREGON UROLOGY INSTITUTE | $46,207 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-03-06 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $596 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-03-06 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $273 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-03-06 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $273 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-03-06 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $273 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-03-06 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $273 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-03-06 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $273 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-03-06 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $273 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-03-06 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $273 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-03-06 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $1,092 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-03-03 | Janssen Research & Development, LLC | OREGON UROLOGY INSTITUTE | $1,314 | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to | 2025 |
| 2025-02-20 | Dendreon Pharmaceuticals LLC | OREGON UROLOGY INSTITUE PC | $42,408 | PROVONE STUDY | 2025 |
| 2025-02-20 | Dendreon Pharmaceuticals LLC | OREGON UROLOGY INSTITUE PC | $550 | PROVONE STUDY | 2025 |
| 2025-02-20 | Dendreon Pharmaceuticals LLC | OREGON UROLOGY INSTITUE PC | $36,029 | PROVONE STUDY | 2025 |
| 2025-02-20 | Dendreon Pharmaceuticals LLC | OREGON UROLOGY INSTITUE PC | $9,948 | PROVONE STUDY | 2025 |
| 2025-02-06 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $1,092 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-02-03 | Janssen Research & Development, LLC | OREGON UROLOGY INSTITUTE | $2,186 | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to | 2025 |
| 2025-02-03 | Janssen Research & Development, LLC | OREGON UROLOGY INSTITUTE | $1,042 | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Lo | 2025 |
| 2025-01-27 | Janssen Research & Development, LLC | OREGON UROLOGY INSTITUTE | $9,739 | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to | 2025 |
| 2025-01-27 | Janssen Research & Development, LLC | OREGON UROLOGY INSTITUTE | $9,739 | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to | 2025 |
| 2025-01-02 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $1,092 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-01-02 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $1,092 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2024-12-31 | Merck Sharp & Dohme LLC | OREGON UROLOGY INSTITUTE | $47,387 | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2024 |
| 2024-12-27 | Merck Sharp & Dohme LLC | OREGON UROLOGY INSTITUTE | $20,974 | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2024 |
| 2024-12-20 | Janssen Research & Development, LLC | OREGON UROLOGY INSTITUTE | $381 | A Randomized Double blind Placebo controlled Phase 3 Study of JNJ56021927 in Subjects with High risk Localized or Locall | 2024 |
| 2024-12-20 | Janssen Research & Development, LLC | OREGON UROLOGY INSTITUTE | $5,168 | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to | 2024 |
| 2024-12-19 | MEDIVATION LLC. | OREGON UROLOGY INSTITUTE PC | $150 | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Springfield, OR, county Lane County, OR, state Oregon; placed by its city name.
| Measure | Place (city or town) Springfield, OR | County Lane County, OR | State Oregon |
|---|---|---|---|
| Population B01003 | 61,499 | 384,207 | 4,254,293 |
| Population, 2020 census P1 | 61,851 | 382,971 | 4,237,256 |
| Median age B01002 | 37.4 | 40.3 | 40.4 |
| Under 18 B01001 | 21.0% | 17.5% | 19.9% |
| 65 and over B01001 | 16.3% | 20.8% | 19.1% |
| Households B11001 | 25,210 | 160,445 | 1,718,422 |
| Foreign born B05002 | 5.9% | 5.4% | 9.8% |
| Median household income B19013 | $68,761 | $71,544 | $83,011 |
| Median family income B19113 | $75,471 | $90,167 | $102,281 |
| Per capita income B19301 | $32,388 | $39,088 | $45,612 |
| Poverty rate B17001 | 14.9% | 15.3% | 11.9% |
| Unemployment rate B23025 | 5.1% | 6.4% | 5.4% |
| Civilian labor force B23025 | 33,041 | 195,670 | 2,183,462 |
| Mean commute (minutes) B08013 | 19.4 | 20.2 | 23.0 |
| Bachelor's degree or higher B15003 | 22.4% | 34.0% | 36.8% |
| Housing units B25001 | 25,905 | 169,788 | 1,857,992 |
| Owner-occupied B25003 | 55.0% | 59.7% | 63.3% |
| Renters B25003 | 45.0% | 40.3% | 36.7% |
| Median home value B25077 | $358,700 | $430,600 | $477,600 |
| Median gross rent B25064 | $1,258 | $1,355 | $1,525 |
| White, not Hispanic B03002 | 74.8% | 78.2% | 71.4% |
| Black B03002 | 0.9% | 1.1% | 1.8% |
| Hispanic or Latino B03002 | 15.1% | 10.5% | 14.7% |
| Asian B03002 | 1.5% | 2.5% | 4.4% |
| American Indian and Alaska Native B03002 | 1.1% | 0.7% | 0.6% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Springfield, OR.
Comments